Research News

In a historic leap for global health, an international team of scientists has developed the world’s first genetically engineered, product-ready snake antivenom — a potential game-changer for treating bites from some of Africa’s most lethal snakes, including cobras, mambas, and rinkhals.

Semaglutide significantly reduced major adverse cardiovascular events in patients with overweight or obesity with cardiovascular disease but without diabetes, as per recent research study conducted by University College London.

A multiple sclerosis patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a clinical trial testing whether this personalised treatment can slow or even halt the progression of the disease.

Addressing the question of whether and how immune cells in the central nervous system traffic out, researchers have now identified a perineural pathway through which the HIV virus can redistribute throughout the body.

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of various tumour types.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the program, evaluated orforglipron versus dapagliflozin, an SGLT-2 inhibitor, in adults with type 2 diabetes inadequately controlled on metformin.

Liver cancer remains one of the worlds most lethal cancers, ranking as the third leading cause of cancer-related deaths. Although surgical advances have improved safety, recurrence after hepatectomy continues to be a major challenge.

Since ancient times, it was thought that painful stomach ulcers were caused by eating spicy foods or having an unhealthy diet. But since then, researchers have found that Helicobacter pylori a common bacterium found in over 60% of the world’s population—was the real culprit behind most stomach ulcers and a high risk for stomach cancer.

HTLV‑1 – the first human retrovirus to be identified, in 1977 – affects at least 5-10 million people globally. It is concentrated in western and central Africa, Latin America, and the Western Pacific Region.